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A 35 year old pregnant woman noted blurred vision in her left eye. After delivering a healthy baby by Caesarean
section, vaginal bleeding occurred from the uterine wound. Two days later she experienced chest pain with ST
elevation in the precordial leads. A dissection of the left anterior descending coronary artery was stented
(Fig. 1AeC). Visual symptoms recurred and a dissection of the left internal carotid artery was conﬁrmed. “How
should I manage this patient?”Objective/Background: In rare genetic vascular syndromes the diagnosis may not be apparent from the
phenotype, but might be important for proper management.
Methods: A previously healthy woman without dysmorphic features presented with pregnancy associated
vascular dissections and aneurysms. Next generation clinical exome sequencing was performed.
Results: The differential diagnosis of spontaneous arterial dissection is outlined. The patient’s diagnosis became
evident after clinical exome sequencing detected a novel missense mutation in the evolutionary conserved region
of SMAD3, conﬁrming the diagnosis of Loeys-Dietz syndrome (LDS) type 3. A brief overview of the various types
of LDS and their management is presented.
Conclusion: Clinical exome sequencing proved useful in diagnosing LDS type 3 where detailed vascular
surveillance and timely intervention with a low threshold is recommended.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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dissectionDIFFERENTIAL DIAGNOSIS OF SPONTANEOUS ARTERIAL
DISECTION
Postpartum status and multiparity are known risk factors for
spontaneous coronary artery dissection, which is associated
with a predisposing arterial disease in 80% of cases.1 Sys-
temic inﬂammatory conditions, such as the vasculitides,
account for a small proportion of spontaneous coronary
artery dissections, while most patients have non-responding author.
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//dx.doi.org/10.1016/j.ejvs.2015.08.003inﬂammatory disease, such as ﬁbromuscular dysplasia or
one of the rare genetic syndromes (e.g., vascular type
Ehlers-Danlos syndrome [EDS], Marfan syndrome, osteo-
genesis imperfecta, familial aortic dissection [also known as
cystic medial necrosis], reticular ﬁber deﬁciency, homo-
cystinuria, alpha-1 antitrypsin deﬁciency or others).1 About
20% of spontaneous coronary artery dissections remain
idiopathic.1 The differential diagnosis of spontaneous ca-
rotid artery dissection is similar to that of coronary
dissection with the addition of autosomal dominant poly-
cystic kidney disease.2
Did the patient’s history, physical examination, and lab-
oratory tests offer any diagnostic clues? The patient’s past
medical history was unremarkable, and her family history
Figure 1. (AeC) Coronary angiography showing (A) a tight stenosis of the mid-left anterior descending coronary artery (LAD) (arrow); (B)
dissection of the LAD progressing to total occlusion on passage of the guide wire (arrows); and (C) successful recanalization of the LAD
after stenting (arrow). (D, E) Magnetic resonance angiograms with three dimensional reconstruction. (D) Long dissection of the left internal
carotid artery (between arrowheads), (E) aneurysm of both common iliac arteries (arrows); aneurysm of the superior mesenteric artery
(lower arrowhead), and of the splenic artery (upper arrowhead). Note the tortuosity of the splenic artery.
Clinical Exome Sequencing 817was negative for premature vascular disease. She was col-
lege educated, successfully employed, married, and had
uncomplicated pregnancies in 2006 and 2009. On clinical
examination, she was proportionally built, without dys-
morphic features or neurological deﬁcit, with a body height
of 174 cm, body mass of 69 kg, and a body mass index of
22.8. There was no marked skin hyperelasticity or joint
hypermobility. Serological screening tests for autoimmune
diseases were negative and the inﬂammatory markers were
normal, which argued against a systemic inﬂammatory
condition such as large artery vasculitis.
The most common cause of spontaneous arterial dissec-
tion is ﬁbromuscular dysplasiada non-inﬂammatory, non-
atherosclerotic disorder predominantly affecting women of
childbearing age.1,2 Fibromuscular dysplasia leads to arterial
stenosis, occlusion, aneurysm, and/or dissectiondmost
often in the renal and carotid arteries.3 The etiology ofﬁbromuscular dysplasia remains unknown, although a ge-
netic predisposition with an autosomal inheritance has been
described in some families.3 Fibromuscular dysplasia has a
characteristic angiographic appearance of a “string of beads”
or, less commonly, circumferential or tubular stenosis,3 none
of which were present on this patient’s angiogram (Fig. 1).
Magnetic resonance angiography (MRA) showed normal
aortic anatomy without dissection, but small aneurysms of
both common iliac arteries were present, as well as a fusi-
form aneurysm of the superior mesenteric artery, which was
the origin of the hepatic artery. The splenic artery was
markedly tortuous and had a small aneurysm (Fig. 1E).
Intracranially, a 3 mm aneurysm was found at the origin of
the left anterior communicating artery.
The absence of dysmorphic features in the patient argued
against Marfan syndrome or osteogenesis imperfecta, and
the patient’s normal cognitive function spoke against
Figure 2. The patient’s leukocyte DNA was subjected to Nextera fragmentation, and sequencing was performed using the TruSight Exome
library preparation protocol (Illumina, San Diego, CA, USA), which included target enrichment for the coding exons of 2,761 genes related
to inherited human diseases. The Illumina MiSeq sequencer was used in paired-end sequencing mode with 150 base pairs sequenced from
each side of the fragments in the library. Over 93% of the sequences targeted in the capture set were covered at least 10 times. Primary
data analyses, including de-multiplexing and fastq generation, were performed using Illumina MiSeq Reporter software. Secondary ana-
lyses were carried out using a custom pipeline, including the BurrowseWheeler algorithm for reading alignment to hg19 human reference
genome assembly, and variant calling using the Genome Analysis Toolkit (GATK) pipeline in accordance with GATK best practice recom-
mendations (Broad Institute, Cambridge, MA, USA). Genetic variants were evaluated by ANNOVAR and snpEff algorithms, and the pre-
dicted pathogenicity was evaluated according to the SIFT, PolyPhen2, and MutationTaster algorithms. Information on the prevalence of
variants in the general population was obtained from the 1000genomes, ESP6500, UK10K, and GoNL sequencing projects. The c.281G>T
variant of SMAD3 was detected in an evolutionary conserved region of SMAD3 and confers the substitution of the evolutionary invariant
amino acid Trp to Leu at position 94 in the transcript of SMAD3.
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with familial aortic dissection/cystic media necrosis. Alpha-1
antitrypsin deﬁciency was unlikely in the absence of lung or
liver disease, and polycystic kidney disease was not present.
Older literature describes reticular ﬁber deﬁciency as an
important cause of dissecting aneurysms of cerebral ar-
teries.4 Reticular ﬁbers are composed mostly of type III
collagen5; therefore, one could expect a signiﬁcant overlap
with vascular type EDS, which is caused mainly by muta-
tions in COL3A1, which codes for type III collagen.6 EDS is a
group of genetic disorders of connective tissue character-
ized by skin hyperextensibility, joint hypermobility, and tis-
sue fragility. The estimated frequency of EDS syndromes is 1
in 5,000, while that of vascular EDS is only about 1 in
100,000.6 Vascular EDS is potentially life threatening, and
differs from the classic and hypermobility forms in the
increased risk of spontaneous vascular or visceral organ
rupture, and the absence of large joint hyperextensibility.6
Eighty percent of individuals with vascular EDS experience
a major vascular event or rupture of an internal organ, for
example gravid uterus, by 40 years of age.6
This patient had the clinical features of vascular EDS, but
before being referred she had already undergone a skin
biopsy, which did not show disorganized collagen structure.
How could the suspected diagnosis of EDS be veriﬁed?
Were there other diagnostic possibilities to be considered?GENETIC TESTING: NEXT GENERATION CLINICAL EXOME
SEQUENCING
In view of the high clinical suspicion of vascular type EDS,
which was not corroborated by skin biopsy, genetic tes-
tingdnext-generation clinical exome sequencing was opted
for.
Although genetic testing is of little value in the acute
setting, for example in a case of acute arterial dissection,
the correct diagnosis may have implications for proper long-
term patient management. Genetic testing used to be slow
and expensive when large arrays of genes were sequenced
serially according to Sanger, or insensitive when a small
number of known gene variants was sought by comparative
genomic hybridization.7 Next-generation sequencing, based
on massively parallel sequencing of clonally ampliﬁed DNA
molecules, coupled with sufﬁcient computational power
and appropriate software for efﬁcient data analysis, has
brought genetic diagnostics into clinical practice at an
affordable price.7,8 An especially useful approach is clinical
exome sequencing, that is concentrating on the roughly 1%
of coding DNA in the human genome, where mutations are
much more likely to have clinical consequences than in the
remaining 99% of non-coding human DNA.9 Genetic testing
is recommended in all patients with suspected genetic
aortic disease and their ﬁrst degree relatives.10,11 The pa-
tient did not have aortic disease in the strict sense, but had
a high probability of a vascular disease syndrome with the
potential to affect the aorta.
Clinical exome sequencing was performed, followed by
bioinformatic analysis and interpretation of genesassociated with inherited monogenic vascular diseases
(ACTA2, COL3A1, COL5A1, COL5A2, PLOD, EFEMP2, FBN1,
FBN2, GATA5, MYH11, MYLK, NOTCH1, SLC2A10, SMAD3,
TGFB2, TGFBR1, TGFBR2). Sequencing data analysis showed
the presence of a heterozygous missense variant in SMAD3
(c.281 G>T, corresponding to an amino acid change
Trp94Leu), located in the MH1 domain of the gene, linking
the patient’s phenotype to Loeys-Dietz syndrome (LDS) type
3. As it resides in a highly evolutionary conserved segment
of SMAD3, which mediates the SMAD3 dependent regula-
tion of the transforming growth factor (TGF)-b pathway, the
c.281 G>T mutation was predicted as pathogenic in a
consensus vote of all three pathogenicity prediction algo-
rithms employed (Fig. 2). The mutation has not been re-
ported previously in any individual in population studies,
nor has it been tracked in the dbSNP v138 database of
human variation (National Center for Biotechnology Infor-
mation). Genetic testing of the patient’s children showed
the same mutation in the eldest daughter, while no ab-
normalities were found in COL3A1, COL5A1, COL5A2, or
PLOD1 in the patient or her children, thus refuting the
original suspected diagnosis of the vascular type EDS and
suggesting the diagnosis of LDS type 3.LDS
LDS is a rare, autosomal dominant genetic disorder associ-
ated with dysregulation of the TGF-b signaling pathway,
which affects connective tissue in many parts of the body
and represents a life threatening condition because of
arterial aneurysms and dissections.12e14 Most cases of LDS,
especially type 1, are characterized by Marfan like skeletal
features with additional craniosynostosis, hypertelorism,
and biﬁd uvula or cleft palate.12e14 In rare cases, especially
LDS type 3, there may be no external dysmorphic features,
which obscures the correct diagnosis.14,15
LDS was ﬁrst described in 2005e06 as a consequence of
mutations in TGFBR1 and TGFBR2.12,13 LDS type 1, caused
by mutations in TGF-b receptor 1 (TGFBR1) mutations, ac-
counts for about 75% of all cases of LDS and is characterized
by aortic dilatation, aneurysms and dissection, pronounced
arterial tortuosity, and by heart defects, hypertelorism, biﬁd
uvula, cleft palate, craniosynostosis, and skeletal problems
similar to that of Marfan syndrome (scoliosis, pectus exca-
vatum or pectus carinatum, and elongated limbs with joint
deformities).12e14 LDS type 2, caused by TGF-b receptor 2
(TGFBR2) mutations, is less severe and is characterized by
aortic dilatation, vascular tortuosity, and soft, translucent
skin; skeletal abnormalities are usually absent.14 Mutations
of SMAD3 cause LDS type 3,14,15 which is characterized by
aortic and arterial aneurysms and dissections, as well as by
osteoarthritis of the knees, joints of the hands, and spine
that usually becomes apparent in early to mid-adult-
hood.14,15 Mutations in TGFB2 cause LDS type 4, which
manifests as aortic aneurysms, vascular tortuosity, and
skeletal manifestations.14 It has been proposed that a mu-
tation in any of these four genes in combination with
arterial aneurysm or dissection or family history of
820 A. Blinc et al.documented LDS is sufﬁcient for establishing the diagnosis
of LDS.14MANAGEMENT OF PATIENTS WITH LDS
The recommended management of patients with LDS con-
sists of vigilant vascular surveillance, blood pressure control,
timely vascular surgical intervention, and orthopedic care
and genetic counseling.14
To reduce hemodynamic stress on the vasculature,
pharmacological beta blockade is regarded as the standard
of care in all patients with syndromic aortic conditions.14
Angiotensin receptor blockers are also recommended in
LDS because they are expected to reduce the overactive
TGF-b signaling pathway.14 However, the data in favor of
angiotensin receptor blockers are based on patients with
Marfan syndrome in whom losartan reduced the rate of
aortic root dilatation.16,17 A recent randomized trial did not
show a beneﬁt of losartan over atenolol in children and
young adults with Marfan syndrome.18 Losartan is effective
in “haploinsufﬁcient” patients with Marfan syndrome with
mutations of FBN1, where a decreased amount of normal
ﬁbrillin-1 is found in connective tissues but less so in
“dominant negative” patients with Marfan syndrome where
an abundance of mutant ﬁbrillin-1 is present.19 In spite of
the lack of evidence based data in patients with LDS, the
recommendation to prescribe an angiotensin receptor
blocker was followed,14 and losartan was added to the
patient’s medications with up-titration to 100 mg/day.
Patients with LDS require echocardiography at least at
yearly intervals to assess the aortic root, ascending aorta,
and heart valves.14 Head to pelvis MRA or computed to-
mography angiography (CTA) should be performed at
diagnosis, after 1 year, and thereafter according to the
location, size, and progression rate of aneurysms, but at
least every 2 years.14 Type B aortic dissections should be
followed aggressively for rapid aortic growth.14 Patients
with LDS should be advised to avoid contact or competitive
sports, isometric exercises, and exercising to exhaustion.14
As aortic dissections and aneurysm ruptures tend to occur
in patients with LDS at smaller dimensions than in Marfan
syndrome and other types of aortic disease, a lower
threshold for vascular surgical intervention has been pro-
posed.10,11,14 The guidelines for patients with LDS syndrome
suggest a surgical threshold in adults with an aortic root
diameter of >4 cm or expansion at a rate of >0.5 cm/year,
a personalized decision in the ascending aorta above a
diameter of 4 cm, a threshold diameter of 4e5 cm in the
descending thoracic aorta, and a threshold of 4.0e4.5 cm in
the abdominal aorta, or an expansion rate of >1 cm/year at
any location.14 The European Society of Cardiology guide-
lines on aortic disease suggest intervening on the ascending
aorta at diameters  4.2 cm,10 while the American guide-
lines on thoracic aortic disease suggest considering surgical
repair at a thoracic aortic diameter of 4.2 cm, determined
by transesophageal echocardiogram, or  4.4 cm by CTA or
MRA.11 Although all these recommendations are based on
expert opinion it is clear that monitoring of patients withLDS should be diligent, and a low threshold for vascular
surgical intervention should be kept in mind. There is
concern about using aortic stent grafts in patients with
genetic aortic aneurysm syndromes for fear that the landing
zones might easily be compromised by the underlying dis-
ease,14 but stent grafts have been successfully used in
aortic replacement where the landing zones were within
existing synthetic grafts from previous operations.20
CONCLUSION
When a patient has a high probability of a genetic vascular
syndrome, clinical exome sequencing is helpful in estab-
lishing the correct diagnosis which is a prerequisite for
management. Clinical exome sequencing established the
diagnosis of LDS type 3 in this patient, which prompted her
caregivers to perform detailed vascular imaging, including
screening for cerebral aneurysms, and keeping in mind the
low threshold for vascular intervention.
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